All In Biotech

Drug Trial Radar · NCT03468478

Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation

Comparison of the Efficacy and Safety of Sirolimus, Everolimus or Mycophenolate in Renal Transplant Recipients Receiving Induction With Anti-thymocyte Globulin, Tacrolimus and Prednisone

Last checked: Nov 19, 2026Latest source record: Apr 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,209 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,209

Actual

Start

Jun 18, 2017

Primary completion

Mar 18, 2021

Study completion Aug 23, 2021

Sponsor

Lead sponsor
Hospital do Rim e HipertensãoAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 16, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was designed to compare 3 immunosuppression regimens: sirolimus and tacrolimus versus everolimus and tacrolimus versus mycophenolate and tacrolimus. The primary outcome is the incidence of cytomegalovirus infection / disease, a relevant medical need in the absence of pharmacological prophylaxis.

Conditions

  • Kidney Transplant Infection

Interventions

  • SirolimusDrug

    sirolimus combined to reduced dose of tacrolimus

  • EverolimusDrug

    everolimus combined to reduced dose of tacrolimus

  • Mycophenolic acidDrug

    Control arm: mycophenolate combined to regular tacrolimus

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Cytomegalovirus Infection or DiseaseTime frame: 12 months follow up

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital do Rim

    São Paulo, São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.